目的 探討乳癖散結(jié)顆粒聯(lián)合枸櫞酸托瑞米芬片治療乳腺增生癥的臨床療效。方法 將湖南中醫(yī)藥大學(xué)第一附屬醫(yī)院在2022年2月—2024年5月收治的92例乳腺增生癥患者作為研究對(duì)象，按隨機(jī)數(shù)字表法將患者分為對(duì)照組和治療組，每組46例。對(duì)照組患者口服枸櫞酸托瑞米芬片，1片/次，1次/d。治療組在對(duì)照組基礎(chǔ)上開(kāi)水沖服乳癖散結(jié)顆粒，1袋/次，3次/d。兩組患者持續(xù)治療45 d。比較兩組患者的治療效果、腫塊大小、主觀疼痛程度、血清指標(biāo)。結(jié)果 治療組的總有效率為93.48%，對(duì)照組的總有效率為78.26%，組間差異顯著（P＜0.05）。治療后，兩組的腫塊顯著縮小（P＜0.05），且治療組縮小程度比對(duì)照組高（P＜0.05）。治療后，兩組患者靜息、按壓VAS評(píng)分均顯著減小（P＜0.05）；治療組的靜息、按壓VAS評(píng)分均小于對(duì)照組（P＜0.05）。治療后，兩組患者的血清血管內(nèi)皮生長(zhǎng)因子（VEGF）、轉(zhuǎn)化生長(zhǎng)因子-β1（TGF-β1）水平低于治療前，血清B細(xì)胞淋巴瘤因子3（Bcl-3）水平高于治療前（P＜0.05）；治療組的血清VEGF、TGF-β1水平低于對(duì)照組，血清Bcl-3水平高于對(duì)照組（P＜0.05）。結(jié)論 乳癖散結(jié)顆粒聯(lián)合枸櫞酸托瑞米芬片可提高乳腺增生癥的療效，進(jìn)一步縮小腫塊大小，減輕疼痛程度，抑制異常組織生長(zhǎng)。

Objective To explore the clinical efficacy of Rupi Sanjie Granules combined with Toremifene Citrate Tablets in treatment of breast hyperplasia. Methods 92 Patients with breast hyperplasia from The First Hospital of Hunan University of Chinese Medicine from February 2022 to May 2024 were selected, and were divided into control group and treatment group using a random number table method, with 46 patients in each group. Patients in the control group were po administered with Toremifen Citrate tablets, 1 tablets/time, once daily. On the basis of the control group, patients in the treatment group were took Rupi Sanjie Granules with boiled water, 1 bag/time, 3 times daily. Two groups of patients were continuously treated for 45 d. The treatment efficacy, tumor size, subjective pain level, and serum indicators between two groups of patients were compared. Results The total effective rate of patients in the treatment group was 93.48%, that of the control group was 78.26%, and the difference between the groups was significant (P < 0.05). After treatment, tumor sizes in both groups were significantly decreased (P < 0.05), and the degree of tumor sizes reduction in the treatment group was higher than that in the control group (P < 0.05). After treatment, the VAS scores of two groups of patients at rest and under pressure were significantly reduced (P < 0.05). The VAS scores at rest and under pressure in the treatment group were lower than those in the control group after treatment (P < 0.05). After treatment, the serum levels of vascular endothelial growth factor (VEGF) and transforming growth factor-β1 (TGF-β1) in both groups of patients were lower than these before treatment , but the serum level of B-cell lymphoma factor 3 (Bcl-3) was higher than these before treatment (P < 0.05). The serum levels of VEGF and TGF-β1 in the treatment group were lower than those in the control group, while the serum levels of Bcl-3 were higher than that in the control group (P < 0.05). Conclusion The combination of Rupi Sanjie Granules and Toremifene Citrate Tablets can improve the efficacy of breast hyperplasia, further reduce tumor size, alleviate pain, and inhibit abnormal tissue growth.

R984

湖南省衛(wèi)生健康委科研計(jì)劃項(xiàng)目(202203075671)